Neurocrine Biosciences NBIX Return on invested capital

Return on invested capital at other companies

Bristol-Myers SquibbBMY

16.7%+8.4pp

Acadia PharmaceuticalsACAD

10%-34.0pp

Crinetics PharmaceuticalsCRNX

-45.1%+1.9pp

Solid Biosciences Inc.SLDB

-191.5%+205pp

BiogenBIIB

4.6%-3.5pp

Rhythm Pharmaceuticals, Inc.RYTM

-197.9%-87.7pp

FAQ

What is Neurocrine Biosciences's return on invested capital?

Neurocrine Biosciences (NBIX) reported return on invested capital of 17.5% in Q1 2026.

How has Neurocrine Biosciences's return on invested capital changed year-over-year?

Neurocrine Biosciences's return on invested capital increased by 40.9% year-over-year, from 12.4% to 17.5%.

What is the long-term trend for Neurocrine Biosciences's return on invested capital?

Over 4 years (2020 to 2025), Neurocrine Biosciences's return on invested capital has grown at a -2.3% compound annual growth rate (CAGR), from 15.8% to 14.4%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.